Biogen Idec Names Cecil B. Pickett President, Research & Development.CAMBRIDGE, Mass. -- Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BIIB BIIB Basic Imagery Interpretation Brief ) announced today that Cecil B. Pickett, Ph.D., has been named President, Research & Development (R&D). Dr. Pickett will join the Biogen Idec Board of Directors, and will report to James C. Mullen, Biogen Idec's President and Chief Executive Officer. "I am delighted to have Cecil Pickett lead our global R&D organization," said Mullen. "We look forward to having him help us continue to attract top talent, advance our organic pipeline, and develop even more R&D partnerships." "Cecil's experience, passion for science, and impressive track record of industry leadership will be a valued addition to our Board of Directors," said Bruce Ross, Biogen Idec's Chairman. Dr. Pickett joins Biogen Idec from Schering-Plough Corporation, where he has held several senior R&D positions since 1993, most recently as Corporate Senior Vice President & President, Schering-Plough Research Institute. In this capacity, Dr. Pickett helped bring several large and small molecule candidates into the Schering-Plough clinical development pipeline. Prior to joining Schering-Plough, he held several senior R&D positions at Merck & Company. Dr. Pickett received his Ph.D. in cell biology from UCLA UCLA University of California at Los Angeles UCLA University Center for Learning Assistance (Illinois State University) UCLA University of Carrollton, TX and Lower Addison, TX and his B.Sc. in biology from California State University Enrollment  at Hayward. About Biogen Idec Biogen Idec creates new standards of care Standards of care are medical or psychological treatment guidelines, and can be general or specific. They specify appropriate treatment protocols based on scientific evidence, and collaboration between medical and/or psychological professionals involved in the treatment of a given in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion